Dec. 15, 2017
It has been shown that biochemical, molecular, and cellular abnormalities in classic AD involve cell loss and is associated with increased activation of pro-death genes and signaling pathways, impaired energy metabolism, mitochondrial dysfunction, chronic oxidative stress, and cerebrovascular disease/cerebral hypoperfusion. Invention shows potential as a pharmaceutical that can reduce, inhibit or reverse calcium dysregulation in brain cells.
The invention is a method that involves administering a molecule that promotes calcium-release stabilization in the ryanodine receptors and/or inositol triphosphate receptors in the brain cells of the patient. It also involves a method for treating Alzheimer’s disease, early-stage AD, elevated risk of AD, mild cognitive impairment, etc. by administering a calcium-release stabilizer that induces reduction, inhibition or reversal of calcium dysregulation.
pharmaceuticals; treatment method; Alzheimer’s disease; mild cognitive impairment (MCI); ryanodine receptors (RyR); inositol triphosphate receptors (InsP3R); brain cells
Method of intervention is targeted specifically to brain cells and has the potential to treat calcium dysregulation that is associated with cognitive decline due to normal aging and/or AD.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
impaired energy metabolism
chronic oxidative stress
cerebrovascular disease/cerebral hypoperfusion
treating alzheimer’s disease
mild cognitive impairment
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium